These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18807123)

  • 1. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
    Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
    Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
    Reichardt P; Von Minckwitz G; Thuss-Patience PC; Jonat W; Kölbl H; Jänicke F; Kieback DG; Kuhn W; Schindler AE; Mohrmann S; Kaufmann M; Lück HJ
    Ann Oncol; 2003 Aug; 14(8):1227-33. PubMed ID: 12881384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
    Liu XH; Man YN; Cao R; Liu C; Wu XZ
    Curr Med Res Opin; 2014 Jun; 30(6):1017-24. PubMed ID: 24528110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
    Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
    Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
    Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
    Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
    Yamamoto D; Iwase S; Tsubota Y; Ariyoshi K; Kawaguchi T; Miyaji T; Sueoka N; Yamamoto C; Teramoto S; Odagiri H; Kitamura K; Nagumo Y; Yamaguchi T
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1183-9. PubMed ID: 25862350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
    Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
    Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
    Amari M; Ishida T; Takeda M; Ohuchi N
    Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.